iSAM Funds UK Ltd Buys 38,914 Shares of Pfizer Inc. $PFE

iSAM Funds UK Ltd grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 128.1% during the 2nd quarter, Holdings Channel reports. The firm owned 69,300 shares of the biopharmaceutical company’s stock after buying an additional 38,914 shares during the period. Pfizer comprises about 1.2% of iSAM Funds UK Ltd’s investment portfolio, making the stock its 13th biggest position. iSAM Funds UK Ltd’s holdings in Pfizer were worth $1,669,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the last quarter. State Street Corp grew its position in shares of Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after acquiring an additional 1,357,756 shares during the period. Geode Capital Management LLC increased its stake in shares of Pfizer by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares during the last quarter. Morgan Stanley increased its stake in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Pfizer in the 4th quarter valued at about $1,830,986,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $29.02 on Thursday. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $29.09. The stock’s 50 day moving average is $25.79 and its 200-day moving average is $26.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $165.42 billion, a price-to-earnings ratio of 38.19, a PEG ratio of 1.92 and a beta of 0.34.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.9%. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly performance: Pfizer reported earnings and revenue above expectations, with quarterly revenue increasing year over year. The results, along with growth in vaccines and oncology, have helped drive renewed investor interest. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Legal overhang reduced: Pfizer’s reported settlement of more than 6,000 Depo-Provera lawsuits removes some litigation uncertainty and may be viewed favorably by investors. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Pipeline activity: Pfizer has begun a Phase 1 study of asthma candidate PF-08103402. Although early-stage programs are not near-term revenue drivers, the trial provides another potential growth asset as the company works to offset future patent expirations. Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1
• Neutral Sentiment: Valuation and dividend appeal: A bullish investment case argues that PFE remains attractive below $30 for patient, income-oriented investors, supported by its dividend and long-term recovery potential. Should You Buy Pfizer Stock Below $30?
• Negative Sentiment: Growth concerns persist: Commentary highlights declining core-business revenue and the approaching patent cliff. Pfizer’s AI strategy is viewed as a longer-term promise rather than evidence of immediate earnings growth. Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
• Negative Sentiment: Bearish sentiment remains visible: Jim Cramer declined to recommend Pfizer despite its dividend, while unusually high put-option activity suggests some traders are positioning for downside or hedging near the recent high. Cramer Won’t Recommend Pfizer Even With Its Dividend

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PFE shares. Wolfe Research reiterated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Guggenheim dropped their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. BMO Capital Markets cut their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Finally, Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.28.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.